| Grantee | Grant description | Grant year | Amount |
|---|---|---|---|
| Yale University | Generation and Characterization of A New As Mouse Model That Recapitulates the Large Deletion of Human 15q11-q13 and A Control Line That Carries A Deletion of All Genes in 15q11-q13 But Ube3a | 2022-12 | $233,299 |
| University of Pennsylvania (Penn) | A. the Ube3a Antisense Transcript (Ube3A-As) Is A Long Non-Coding Mrna That Silences Expression of the Paternal Ube3a Gene in Neurons. Interruption of This Imprinting Phenomenon Can Be Done Through Asos, Crispr-Grna Or Other Technologies Like Microrna (Mirna). This Project Is Aiming To Develop A Strategy To Suppress the Ube3A-As in the Mouse Model of As Using Mirnas. Advantages To Mirna Are That They Are Subject To Endogenous Cellular Processing and Regulation, Which Can Help Circumvent Issues Related To Overexpression of Exogenous Genetic Material (With Ube3a Replacement), and the Need for Repeated Redosing (With Asos). Mirna Is Thought To Be Advantageous Over Shrna Due To Endogenous Cellular Processing and Regulation Compared To Overexpression You Could Get With Shrna. | 2022-12 | $115,121 |
| Grantmaker | Grantmaker tax period | Description | Amount |
|---|---|---|---|
| Fidelity Investments Charitable Gift Fund | 2023-06 | For Grant Recipient's Exempt Purposes | $93,267 |
| American Online Giving Foundation | 2023-03 | General Support | $62,826 |
| Texas Children's Hospital (TCS) | 2023-09 | General Support | $30,000 |
| ...and 19 more grants received totalling $382,675 | |||
| Name | Title | Compensation | Date of data |
|---|---|---|---|
| Alana Newhouse | President and Chief Executive Officer | $50,000 | 2022-12-31 |
| Kena Richert | Chief Financial Officer and Treasurer / Treasurer and Cheif Financial Officer | $188,000 | 2022-12-31 |
| Megan Cross | Director / Chief Information Officer / Communications Officer | $0 | 2022-12-31 |
| Allyson Berent | Chief Science Officer | $0 | 2022-12-31 |
| Maiddy Dunigan | Former Officer and Chief Operating Officer / Vice Chairperson and Chief Executive Officer | $104,167 | 2021-12-31 |
| ...and 6 more key personnel | |||
| Revenues | FYE 12/2022 |
|---|---|
| Total grants, contributions, etc. | $4,948,249 |
| Program services | $355,507 |
| Investment income and dividends | $508,992 |
| Tax-exempt bond proceeds | $0 |
| Royalty revenue | $0 |
| Net rental income | $0 |
| Net gain from sale of non-inventory assets | $47,271,158 |
| Net income from fundraising events | $-606,087 |
| Net income from gaming activities | $0 |
| Net income from sales of inventory | $0 |
| Miscellaneous revenues | $0 |
| Total revenues | $52,477,819 |
| Fiscal year ending | Date received by IRS | Form | PDF link |
|---|---|---|---|
| 2022-12 | 2023-11-15 | 990 | View PDF |
| 2021-12 | 2022-11-15 | 990 | View PDF |
| 2020-12 | 2021-10-15 | 990 | View PDF |
| 2019-12 | 2021-02-17 | 990 | View PDF |
| 2018-12 | 2020-01-28 | 990 | View PDF |
| ...and 10 more Form 990s | |||
| Organization | Type | Location | Revenue |
|---|---|---|---|
| Alexs Lemonade Stand Foundation (ALSF) | 501(c)(3) | Wynnewood, PA | $31,723,244 |
| Connectability of MN | 501(c)(3) | Waite Park, MN | $13,192,531 |
| Prostate Cancer Foundation | 501(c)(3) | Santa Monica, CA | $57,291,095 |
| Alzheimers Drug Discovery Foundation (ADDF) | 501(c)(3) | New York, NY | $254,027,105 |
| DKMS | 501(c)(3) | New York, NY | $47,341,531 |
| Foundation Fighting Blindness (FFB) | 501(c)(3) | Columbia, MD | $30,437,892 |
| Children's National Hospital Foundation | 501(c)(3) | Washington, DC | $123,280,101 |
| Hope and Help Center of Central Florida | 501(c)(3) | Aloma, FL | $27,958,210 |
| Fistula Foundation | 501(c)(3) | San Jose, CA | $14,403,216 |
| Elton John Aids Foundation (EJAF) | 501(c)(3) | New York, NY | $29,188,898 |
Want updates when Foundation for Angelman Syndrome Therapeutics has new information, or want to find more organizations like Foundation for Angelman Syndrome Therapeutics?
Create free Cause IQ account